Willow Biosciences, Inc. 是一家生物技術公司,專注於研究、開發和商業化植物來源的成分,應用於消費護理、食品飲料以及藥品產品。公司總部位於加拿大亞伯達省卡加利,目前擁有19名全職員工。该公司於2017年9月14日首次公開發行股票(IPO)。公司致力於開發和生產通過精密發酵技術製造的功能性成分,主要面向健康保健、食品飲料及個人護理市場。其FutureGrown生物技術平台以永續發展為核心進行生產。公司的商業化產品包括大麻二酚CBG,這是一種具有抗菌、抗炎和抗氧化特性的大麻素。公司還提供名為BioOxi的生物氧化技術平台。透過利用BioOxi技術,商業合作夥伴能夠革新含氧和羥基化功能性成分的製造過程,例如類固醇、多酚、氧萜類以及其他特定目標成分。此外,公司也正在開發基於BioOxi的工藝,用於生產通用活性藥物成分(API)氫化可的松及其衍生物。其他管線產品還包括熊去氧膽酸(UCAC)、蝦青素、β-胡蘿蔔素等。
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for CANSF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: CANSF is a Buy candidate.
CANSF stock price ended at $0.11 on 星期五, after rising 0.00%
On the latest trading day Feb 06, 2026, the stock price of CANSF rose by 0.00%, climbing from $0.11 to $0.11. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.11 and a high of $0.11. Notably, trading volume dropped by 31.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 31.5K shares were traded, equating to a market value of approximately --.